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a b s t r a c t
Dihomo-γ-linolenic acid (DGLA) and its downstream fatty acid arachidonic acid (AA) are both
nutritionally important ω–6 polyunsaturated fatty acids (ω–6s). Evidence shows that, via COX-
mediated peroxidation, DGLA and its metabolites (1-series prostaglandins) are associated with anti-
tumor activity, while AA and its metabolites (2-series prostaglandins) could be tightly implicated in
various cancer diseases. However, it still remains a mystery why DGLA and AA possess contrasting
bioactivities. Our previous studies showed that DGLA could go through an exclusive C-8 oxygenation
pathway during COX-catalyzed lipid peroxidation in addition to a C-15 oxygenation pathway shared by
both DGLA and AA, and that the exclusive C-8 oxygenation could lead to the production of distinct
DGLA's free radical derivatives that may be correlated with DGLA's anti-proliferation activity. In the
present work, we further investigate the anti-cancer effect of DGLA's free radical derivatives and their
associated molecular mechanisms. Our study shows that the exclusive DGLA's free radical derivatives
from C-8 oxygenation lead to cell growth inhibition, cell cycle arrest and apoptosis in the human colon
cancer cell line HCA-7 colony 29, probably by up-regulating the cancer suppressor p53 and the cell cycle
inhibitor p27. In addition, these exclusive radical derivatives were also able to enhance the efﬁcacy of
5-Fluorouracil (5-FU), a widely used chemo-drug for colon cancer. For the ﬁrst time, we show how
DGLA's radical pathway and metabolites are associated with DGLA's anti-cancer activities and able to
sensitize colon cancer cells to chemo-drugs such as 5-FU. Our ﬁndings could be used to guide future
development of a combined chemotherapy and dietary care strategy for colon cancer treatment.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
Introduction
There are two major types of polyunsaturated fatty acids
(PUFAs), namely, ω6s and ω–3s. The ω–3s, such as eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA), are mainly
found in seafood and are extensively studied for their beneﬁcial
effects, including improvement of cognitive ability and prevention
of cancer and cardiovascular diseases [1–4]. The ω6s, such as
dihomo-γ-linolenic acid (DGLA) and arachidonic acid (AA), present
in most plant oils, are more abundant in our daily diet than ω–3s.
However, research on ω–6s' beneﬁcial effects on human health has
received much less attention. Upon catalysis of cyclooxygenase
(COX), both DGLA and AA can undergo radical-mediated lipid
peroxidation and produce prostaglandins: 1-series (PGs-1) and
2-series prostaglandins (PGs-2), respectively. It has been widely
accepted that AA could be tightly implicated in inﬂammatory
disorders and cancer development due to the formation of PGs-2
[5–10]. On the other hand, increasing evidence has suggested that
DGLA, the precursor of AA (converted from DGLA by delta-5
desaturase, D5D), may represent an exceptional ω–6 by virtue of
its anti-inﬂammatory and anti-cancer effects [11–17]. For instance,
a dietary DGLA supplement helped to prevent atherosclerosis in
ApoE-deﬁcient mice; treatment with PGs-1 led to anti-neoplastic
effects in B16-F10 murine melanoma cells; and DGLA treatment
exerted direct cytotoxicity towards human cervical carcinoma cells
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(both drug-sensitive and resistant) [13,15,16]. Although evidence
showed that DGLA's bioactivities were partially attributable to its
COX-mediated metabolites, e.g., PGs-1 and/or free radicals, how
DGLA could affect cancer cell growth still remains unclear.
COX-2, a key enzyme regulating PUFA peroxidation, is over-
expressed in 80–90% of colon cancer cells and closely implicated
in cancer development [18–20]. Under the catalysis of COX, both
DGLA and its downstream PUFA (e.g., AA) can undergo free
radical-mediated lipid peroxidation to produce a variety of free
radical species as well as PGs. A number of research efforts have
been focused on PUFAs' and PGs' diverse bioactivities; some of
them suggested that PUFAs may regulate cell growth indepen-
dently of PGs [5,11,12,15,21]. Although free radical-mediated
activity from COX-catalyzed lipid peroxidation has been well
accepted, the potential bioactivity of individual free radical inter-
mediates has not been investigated previously due to the lack of
appropriate methods to identify and characterize the free radical
species.
Using a novel HPLC/ESR/MS combined technique, our previous
study successfully detected and identiﬁed major free radical
metabolites formed from COX/DGLA and COX/AA peroxidation
[22–26]. We showed that despite a common C-15 oxygenation
pathway shared by both DGLA and AA (from the same structural
moiety), there is a C-8 oxygenation pathway present only in COX/
DGLA peroxidation (Scheme 1) [23,24]. This exclusive C-8 oxyge-
nation leads to the production of two exclusive DGLA's free radical
metabolites, dC7H13O2 and dC8H15O3 (observed as POBN-trapped
adducts [23,24]), which are expected to form the corresponding
radical derivatives heptanoic acid (HTA) and 8-hydroxyoctanoic
acid (8-HOA), respectively (Scheme 1). In the present study, these
radical derivatives along with 1-hexanol (HEX, the common
radical derivative formed from both AA and DGLA) were directly
used to test their potential anti-cancer activity and mechanisms in
HCA-7 colony 29 cells, a human colon cancer cell line with high
COX expression. Our results suggest that the exclusive DGLA's free
radical derivatives (and therefore COX-catalyzed DGLA peroxida-
tion) lead to cell growth inhibition, cell cycle arrest and apoptosis
in colon cancer cells, probably by up-regulating the cancer
suppressor p53 and cell cycle inhibitor p27.
The major obstacle for cancer chemotherapy has been drug
resistance. For example, insensitivity to 5-Fluorouracil (5-FU),
a commonly used chemotherapy drug in colon cancer treatment,
has been reported in many colon cancer cell lines [27,28,31].
Various combination treatments of 5-FU with other chemo-drugs
and agents have been tested in order to improve 5-FU's efﬁcacy
[29–32]. For example, the combined treatment of 5-FU with
a COX inhibitor to regulate PUFA metabolism (especially to inhibit
COX/AA metabolism to limit PGs-2 formation) has been shown to
be a promising strategy for colon cancer therapy [31]. Here, we
have proposed and demonstrated that the exclusive DGLA's radical
derivatives, and therefore the radical reactions of COX-catalyzed
DGLA peroxidation, actually sensitize HCA-7 colony 29 colon
cancer cells to the chemotherapy drug 5-FU. Our research ﬁndings
could be used to guide the development of a combined che-
motherapy and dietary care strategy for colon cancer treatment by
taking advantage of the commonly high level of COX in colon
cancer cells and a more pervasive PUFA in the daily diet (ω6
DGLA, instead of ω3s).
Methods and materials
Cell line
The human colon cancer cell line HCA-7 colony 29 (European
Collection of Cell Cultures, Salisbury, UK) was grown in Dulbecco's
modiﬁed Eagle's medium high-glucose medium (Thermo Fisher
Scientiﬁc, UT, USA) supplemented with 10% fetal bovine serum
(Thermo Fisher Scientiﬁc, UT, USA) and cultured in an incubator
containing a 95% humidiﬁed atmosphere with 5% CO2 at 37 1C.
Cells were sub-cultured at a ratio of 1:5–1:8 after they had
reached 90% conﬂuency.
Detection of PUFAs and PGs from DGLA-treated cells
The PUFAs and PGs from HCA-7 colony 29 cells treated with
DGLA were quantiﬁed via LC/MS analysis as described elsewhere
[24]. Brieﬂy, 2106 cells (in 4 mL cell culture medium) were
seeded overnight in a 100-mm petri dish at 30–40% conﬂuency
and treated with DGLA (100 mM). At different time points, 2 mL
of cell culture medium was collected and mixed with internal
standards (AA-d8, DGLA-d6, PGE1-d4 and PGE2-d9). Then 0.45 mL
of methanol and 0.55 mL water were added to make a total of
3 mL of 15% methanol solution. The mixture was vortexed for
1 min and set on ice for 30 min. After it was centrifuged for 15 min
at 3000 rpm, the supernatant was collected and adjusted to pH
3.0, then subjected to solid phase extraction (SPE) using a reverse
phase SPE cartridge (SampliQ Silica C18 ODS, Agilent, CA, USA).
The extract was eluted with 2 mL ethyl acetate, and the elution
dried under vacuum and reconstituted with 100 mL ethanol for
LC/MS analysis.
The LC/MS system consisted of an Agilent 1200 series HPLC
system and an Agilent 6300 LC/MSD SL ion trap mass system.
LC separations were performed on a C18 column (Zorbax Eclipse-XDB,
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Scheme 1. Proposed pathway and formation of radical derivatives in COX-catalyzed DGLA peroxidation. During the COX-catalyzed lipid peroxidation, DGLA can go through
a unique C-8 oxygenation reaction pathway, in addition to a C-15 oxygenation pathway shared by both of DGLA and AA. The C-8 oxygenation produces two exclusive DGLA-
derived free radical metabolites, dC7H13O2 and dC8H15O3, while the C15 pathway produces two common radical metabolites, dC6H13O and dC5H11. The asterisked products,
heptanoic acid (HTA), 8-OH-octanoic acid (8-HOA) and 1-hexanol (HEX), are expected to form from free radicals by abstracting an Hd from the environment in the absence of
the spin trapping agent POBN. The common free radical dC5H11 produced via the C15 pathway is mainly present in the gas phase, thus was not tested in this study.
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4.675mm, 3.5 μm) with an injection volume of 5 μL, ﬂow rate at
0.8 mL/min and mobile phases of A: H2O-0.1% HOAc, and B: ACN-0.1%
HOAc. Gradients were (1) 0–12min (isocratic), 68% A and 32% B;
(2) 12–14min, 68–44% A and 32–56% B; (3) 14–28min (isocratic),
44% A and 56% B; (4) 28–30min, 44–14% A and 56–86% B; (5)
30–38min,14–4% A and 86–95% B; and (6) 38–44min (isocratic), 5% A
and 95% B. MS settings were as follows: electrospray ionization in
negative mode; total ion current (TIC) chromatograms were per-
formed in full mass scan mode (m/z 50 to m/z 600); nebulizer press,
15 psi; dry gas ﬂow rate, 5 L/min; dry temperature, 325 1C; compound
stability, 20%; number of scans, 50. The concentrations of PUFAs and
PGs were quantiﬁed by comparing the ratios of the peak areas of the
PUFAs and PGs to the internal standards.
Detection of free radicals from DGLA-treated cells
The free radicals produced from HCA-7 colony 29 cells treated
with DGLA were detected and quantiﬁed via LC/MS analysis along
with spin trapping methods as described elsewhere [24]. Brieﬂy,
2106 cells (in 3 mL phenol red free cell culture medium) were
seeded overnight in a 100 mm petri dish at 30–40% conﬂuency
and treated with POBN (α-[4–pyridyl–1–oxide]-N-tert-butyl
nitrone, 20 mM) and DGLA (100 mM) to start the peroxidation
and spin-trapping reaction. At different time points, the cell
culture medium and cell homogenate were collected and mixed
with an equal volume of acetonitrile (ACN) to stop the reaction.
Then the mixture was vortexed and centrifuged for 15 min at
3000 rpm. The supernatant was collected and subjected to SPE
using a mixed-mode anion exchange SPE cartridge (Oasis MAX,
Waters, MA, USA), followed by LC/MS analysis. Instead of detecting
the ESR-active POBN-trapped free radical adduct, we actually
measured the reduced form of radical adducts (e.g. hydroxyla-
mines) since they are a more stable redox form and could
accumulate during incubation [24].
The same LC/MS system was employed as used in the detection
of PUFAs and PGs. LC separation was performed with the injection
volume of 40 μL, ﬂow rate at 0.8 mL/min and gradient of: (1)
0–5 min, 90–73% A and 10–27% B; (2) 5–25 min (isocratic), 73% A
and 27% B; (3) 25–40 min, 73–30% A and 27–70% B; (4) 40–43 min,
30–5% A and 70 to 95% B; and (5) 43–50 min (isocratic), 5% A
and 95% B. MS settings are as follows: electrospray ionization in
positive mode; TIC was performed in full mass scan mode (m/z 50
to m/z 600); capillary voltage, 4500 V; nebulizer press, 20 psi;
dry gas ﬂow rate, 8 L/min; dry temperature, 60 1C; compound
stability, 20%; and number of scans, 50. An extracted ion current
chromatogram (EIC) was obtained to acquire the MS proﬁle of the
individual POBN trapped radical adduct. A deuterated spin trap
(d9-POBN) was used as an internal standard for quantiﬁcation as
described elsewhere [22,24,33,34].
Cell proliferation assay (MTS)
Cell proliferation after different treatments was assessed using
CellTiters 96 Aqueous One Solution Reagent (Promega, Madison,
WI, USA) according to the manufacturer's instructions. Brieﬂy, the
cells were seeded at 8000 cells (in 100 μL medium) per well into
96-well plates, incubated overnight to allow them to attach, then
exposed to different treatments, e.g., DGLA's radical derivatives
and PGs (0.1 to 10 μM), 5-FU (0.25 to 1.0 mM), and a combination
(5-FU and a radical derivative). After 48 h incubation at 37 1C,
20 mL per well of CellTiters 96 Aqueous One Solution Reagent was
added to each well. After additional 4 h incubation in the incu-
bator, the quantity of formazan product, which is proportional to
the number of living cells, was assessed by recording the absor-
bance at 490 nm with a 96-well plate reader (SpectraMax M5;
Molecular Devices). Cell viability was calculated as a percentage of
the control group (treated with vehicle).
Cell cycle analysis (PI staining)
Cells were seeded at 40% conﬂuency and incubated overnight
to allow them to attach. After being exposed to different treat-
ments (DGLA's radical derivatives and PGs 1.0 μM) for 48 h, cells
were harvested, washed with PBS and ﬁxed with 1 mL of cold 70%
ethanol at 1106 cells/mL for 30 min at 4 1C. After centrifugation,
the supernatant was discarded. The cells were washed with PBS,
centrifuged and treated with 10 μL ribonuclease (10 mg/mL) at
room temperature for 5 min. Then 400 μL of propidium iodide (PI,
50 μg/mL) was added to the sample. The cell cycle distribution was
measured after a 30 min incubation using an Accuri C6 ﬂow
cytometer (Becton–Dickinson, NJ, USA), and 10,000 cells were
counted for each sample. The percentage of cells in different
phases of the cell cycle was analyzed by FlowJo (TreeStar, Ashland,
OR, USA).
Cell apoptosis assay (Annexin V-FITC/PI staining)
Cell apoptosis was assessed using an Annexin V Apoptosis
Detection Kit I (BD Pharmingen™, NJ, USA) according to the
manufacturer's instructions. Brieﬂy, the cells were seeded over-
night at 40% conﬂuency and exposed to different treatments,
including radical derivatives (1.0 μM), 5-FU (0.5 mM), and a
combination. Then the cells were trypsinized, washed with cold
PBS and re-suspended in 1 binding buffer at a concentration of
1106 cells/mL. After 100 μL of the sample solution was trans-
ferred to a new tube, 5 μL of FITC Annexin V and 5 μL of PI solution
were added. The cells were gently vortexed and incubated for
15 min at 25 1C in the dark. Then 400 μL of 1 binding buffer was
added to each sample. The effect of different treatments on cell
apoptosis was determined by an Accuri C6 ﬂow cytometer within
1 h, and 10,000 cells were counted for each sample. Unstained
cells and cells stained with FITC Annexin V only and PI only were
used as controls to set up compensation and quadrants. Data was
analyzed by FlowJo.
Western blot
Cells were seeded, incubated overnight and exposed to differ-
ent treatments. After 48 h of treatment, the protein was extracted
and quantiﬁed. Equal amounts of protein extract (50 mg) were
loaded into each well of 10% SDS-PAGE gels and run at a constant
current of 30 mA for 1 h. The proteins were then transferred
to nitrocellulose membranes at a constant voltage of 80 V for 2 h
on ice. Membranes were blocked with 5% (w/v) non-fat milk in
1 Tris base saline solution with Tween-20 (TBS-T) for 15 min at
room temperature. Then the membranes were incubated with
primary antibodies (used at 1:600 dilution, Cell Signaling, MA,
USA) overnight at 4 1C with continuous rocking. Membranes were
washed 3 times for 5 min each with 1 TBS-T, then incubated
with horseradish peroxidase (HRP)-conjugated secondary anti-
body (used at 1:2000 dilution, Cell Signaling, MA, USA) for 1 h at
room temperature with continuous rocking. After washing 3 times
with 1 TBS-T, the membranes were incubated in ECL Western
blot substrates (Pierce, Thermo Fisher Scientiﬁc, UT, USA) for
1 min, and exposed to X-ray ﬁlm (Phoenix Research Products,
NC, USA). Luminescence signals were captured on a Mini-Medical
Automatic Film Processor (Imageworks) with β-actin used as a
loading control.
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Statistics
All data was assessed using an unpaired Student's t-test.
A p value r0.05 was considered signiﬁcant.
Results
Measurement of DGLA-derived radicals, PUFAs, and PGs from
DGLA-treated colon cancer cells
LC/MS analysis was applied to quantify PUFAs, PGs and DGLA-
derived free radicals (in reduced form, hydroxylamines) from
2106 HCA-7 colony 29 cells treated with 100 μM of DGLA for
up to 48 h. Among the three DGLA's free radical metabolites
tested, the POBN adduct of the 1-hexanol radical (the common
product formed from both DGLA and AA) was the most abundant
product (79.2475.68 nM, Table 1) at 12 h of incubation. The two
exclusive DGLA's free radicals, heptanoic acid radical and 8-
hydroxyoctanoic acid radical, were much less abundant at up to
48 h at 7.2870.79 and 8.4970.39 nM, respectively.
Our data also showed that PGE1 (from COX-catalyzed DGLA
peroxidation) was accumulated during the ﬁrst 24 h of incubation,
reaching 146 nM before it started to decrease (Table 1). Mean-
while, a notable accumulation of PGE2 (from COX-catalyzed AA
peroxidation) became dominant over the PGE1 and reached
113 nM at 48 h. The effective accumulation of PGE2 from
DGLA-treated cells indicated cellular D5D-mediated conversion of
DGLA to AA. This conversionwas conﬁrmed by the measurement of
much more AA (69.7478.04) than DGLA (30.9376.47 nM) in the
cells treated with DGLA for 48 h. We also observed the formation of
an exclusive AA radical (a carbon–carbon double bond-centered
free radical), seen as the hydroxylamine of a POBN adduct with m/z
449, from HCA-7 cells after a 12 h incubation with DGLA [24]. The
accumulation of AA as well as the exclusive AA radical at certain
time points was also correlated with improved cell proliferation vs.
the time points when no or limited AA and PGs-2 were accumu-
lated (data not shown).
DGLA's radical derivatives attenuate colon cancer cell proliferation
As the major metabolites from COX-catalyzed PUFA peroxida-
tion, prostaglandins have been reported to possess diverse bio-
activities, including anti-inﬂammation and anti-cancer growth
[5,11,12,15]. We thus directly tested the effects on colon cancer
cell growth of a range of PGs concentrations (0.1 μM–10 μM).
This concentration range was chosen based on the PG production
proﬁle from our cell experiments, e.g., 0.1 μM PGs were mea-
sured at 48 h from cells treated with 100 μM DGLA (Table 1). Our
experiments showed that neither PGE1 nor PGE2 at the tested
concentrations inﬂuenced proliferation of HCA-7 colony 29 cells at
48 h (Fig. 1).
We further tested the effect of three of DGLA's free radical
derivatives, HTA, 8-HOA and HEX, on colon cancer cell growth in
the range of 0.1 μM to 10 μM (Table 1). Our results showed that
the two exclusive DGLA's radical derivatives, 8-HOA and HTA,
both inﬂuenced proliferation of HCA-7 colony 29 cells at 1.0 μM;
8-HOA exerted the most signiﬁcant anti-proliferative effect. How-
ever, HEX, the common product of AA and DGLA, did not inﬂuence
cell proliferation at the tested concentrations (Fig. 1). This com-
parison experiment indicates that, at certain concentrations, it is
the exclusive DGLA's free radical derivatives from COX-catalyzed
lipid peroxidation, rather than PGs, that are actually responsible
for DGLA's anti-cancer bioactivities.
DGLA's radical derivatives arrest cell cycle progression
In order to understand how DGLA could regulate colon cancer
cell growth, the HCA-7 colony 29 cells were treated with three of
DGLA's free radical derivatives, HEX, HTA and 8-HOA, at 1.0 μM for
48 h. Cell cycle distribution analysis (via ﬂow cytometer after PI
staining) suggested that the exclusive DGLA's radical derivative
(8-HOA) could induce G1 arrest (50.6% cells in G1) during the cell
cycle progression compared to control (39.3% in G1). However, no
signiﬁcant changes were observed from the other two radical
derivatives (42.9% and 40.6% cells in G1 phase, respectively, Fig. 2).
Again, when the same amounts of PGs were used to treat cells,
Table 1
Proﬁle of PUFAs, PGs, and free radicals (trapped by POBN) from HCA-7 cells treated with DGLA (100 μM). PUFAs and PGs from 2106 cells treated with DGLA (100 μM) were
measured via LC/MS analysis using internal standards, including AA-d8, DGLA-d6, PGE1-d4 and PGE2-d9. The formation of free radicals (trapped by POBN) from 2106 cells
treated with POBN (20 mM) and DGLA (100 μM) was quantiﬁed by LC/MS analysis. Deuterated-POBN (d9-POBN) was used as an internal standard for hydroxylamine
quantiﬁcation [22–24,27]. Data are represented as mean7SD, n¼3.
Time (h) [PUFAs] (nM) [PGs] (nM) [DGLA free radicals] (nM) trapped by POBN as hydroxylamine
DGLA AA PGE1 PGE2 HEX HTA 8-HOA
12 562.679.556 301.0755.77 86.57713.55 85.1379.277 79.2475.685 7.28270.793 7.14270.866
24 541.477.938 304.0760.29 145.978.712 104.5726.58 65.6974.531 5.80071.10 8.48870.386
48 30.9376.474 69.7478.040 71.3672.627 113.2721.26 59.4773.850 4.65470.693 6.97870.750
Fig. 1. Comparison of cell growth responses of PGs vs. DGLA's radical derivatives. HCA-7 colony 29 cells were treated with A: PGs1 and PGs2, respectively, at 0.1 to 10 μM for
48 h; and B: DGLA's radical derivatives (HEX, HTA and 8-HOA) at 0.1–10 μM for 48 h. Cell proliferation was examined by the MTS assay. Cell viability was presented as the
percentage compared to control (treated with vehicle). Data represented three separate experiments run in triplicate per condition. (npo0.05).
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there were no differences in cell cycle distribution observed vs.
control (data not shown).
To investigate the mechanism of the observed cell cycle arrest,
we also tested various molecular targets that could be involved in
cell cycle progression, including the cell cycle inhibitors p21 and
p27, and cyclin D. Of these targets, p27 was found to be up-
regulated by treatment with 8-HOA, which could be responsible
for the observed cellular G1 arrest (Fig. 2).
DGLA's radical derivatives induce cell apoptosis
We further assessed cell apoptosis via the FITC Annexin V/PI
double staining method to determine whether DGLA's radical
derivatives could induce cell death by promoting cell apoptosis.
Consistent with the cell proliferation proﬁle (Fig. 1), the two
exclusive DGLA's radical derivatives, e.g., 8-HOA and HTA, pro-
moted apoptosis of HCA-7 colony 29 cells. For example, we
observed a signiﬁcantly increased cell population in early (8.76%)
and late (4.26%) apoptosis from the 8-HOA treatment compared to
the control (4.24% and 2.68%, respectively, Fig. 3), while there was
again almost no effect from the HEX treatment on apoptosis
compared to the control.
In order to understand the mechanism of apoptosis in HCA-7
colony 29 cells induced by DGLA's radical derivatives, we also
examined two key proteins that regulate the apoptotic pathway:
the cancer suppressor p53 and the initiator caspase 9. Our data
showed that the exclusive DGLA's radical derivatives HTA and
8-HOA signiﬁcantly inﬂuenced p53 expression levels in cells, and
the up-regulated p53 could be responsible for the promoted cell
apoptosis. However, no signiﬁcant changes were observed in pro-
caspase 9 levels for any of the three DGLA's radical derivatives
(Fig. 3).
DGLA's radical derivatives enhance the cytotoxicity of 5-FU
5-FU, a pyrimidine analog, is the most widely used chemo-drug
for colon cancer therapy. It can be incorporated into RNA and DNA
and interfere with nucleoside metabolism, thereby leading to cell
death [35–40]. However, it is known that many cancer cell lines
exhibit drug resistance toward 5-FU treatment [27–28,31]. The
IC50 of 5-FU (1.0 mM) for HCA-7 colony 29 cells was obtained
from our experiment (Fig. 4) in agreement with other research
[31]. We then asked whether DGLA's radical derivatives could be
used to enhance the cytotoxicity of 5-FU to HCA-7 colony 29 cells.
A decreased IC 50 (0.5 mM) for 5-FU was achieved when HCA-7
colony 29 cells were co-treated with 5-FU and DGLA's radical
derivatives (e.g. 1.0 μM 8-HOA). The ability to improve 5-FU's
efﬁcacy with the exclusive DGLA's radical derivatives, might
represent a potential strategy for colon cancer treatment using a
combination of this chemotherapy drug and dietary care. We also
found that co-treatment with DGLA (100 μM) could further
decrease 5-FU's IC50 (0.2 mM) if D5D knockdown HCA-7 colony
29 cells were used (data not shown).
Evidence suggests that 5-FU-induced cytotoxicity is also asso-
ciated with apoptotic progress [37–40], similar to our observed
anti-cancer effects from DGLA's radical derivatives. We observed
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Fig. 2. Effect of DGLA's radical derivatives on cell cycle distribution. A: Cell cycle distribution of HCA-7 colony 29 cells treated with DGLA's radical derivatives as well as PGs
at 1.0 μM for 48 h; B: p27 expression in Western blot after 48 h of treatment with DGLA's radical derivatives (1.0 μM); and C: Quantiﬁcation of p27 expression rate compared
to control (treated with vehicle). The p27 expression rate in individual treatments was calculated as the ratio to beta-actin, and the rate in the control group was normalized
to 1. (npo0.05 from nZ3).
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that the combined treatment with 5-FU (0.5 mM) and 8-HOA
(1.0 μM) induced cell apoptosis to a greater extent than 5-FU or
8-HOA treatment alone (Fig. 3), while combinations with HTA and
HEX did not induce further apoptosis (Fig. 5). Further mechanistic
studies also showed that not only did 5-FU and 8-HOA alone
inﬂuence cellular p53 level, but that the combination also
signiﬁcantly up-regulated the level of p53 expression (Fig. 5). In
addition, the observed activation of pro-caspase 9 with the
combined treatment suggests that certain caspase pathways may
be responsible for promoting cell apoptosis from the combination
of 5-FU and 8-HOA.
Discussion
Previous studies suggested that DGLA could produce two
exclusive free radicals through a unique C-8 oxygenation during
COX-catalyzed lipid peroxidation, and that the radical derivatives
formed might be responsible for DGLA's anti-cancer activities
[23–26]. In the present study, we have further investigated the
effects and mechanism of DGLA's free radical derivatives on the
colon cancer cell growth response, i.e., cell proliferation, cell cycle
distribution, and apoptosis, with the HCA-7 colony 29 cell line. We
also discovered that the exclusive DGLA's free radical derivatives
can enhance 5-FU's cytotoxicity towards HCA-7 colony 29 cells.
The outcome of this study might guide us to design a novel
strategy combining the chemo-drug and dietary care in colon
cancer treatment in the near future.
Quantiﬁcation of PUFAs, PGs, and free radicals (spin trapped)
showed that the amount of AA (and related metabolite PGE2)
dominated over DGLA (and related metabolite PGE1) in HCA-7
colony 29 cells after 48 h of DGLA treatment (Table 1). The results
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Fig. 3. Effect of DGLA's radical derivatives on cell apoptosis. A: Cell apoptosis analysis of HCA-7 colony 29 cells treated with DGLA's radical derivatives at 1.0 μM for 48 h.
Cell apoptosis was tested via FITC Annexin V/PI double staining; B: p53 and pro-caspase 9 expression in Western blot after 48 h of treatment with DGLA's radical derivatives
(1.0 μM); and C: Quantiﬁcation of p53 and pro-caspase 9 expression rate compared to control (treated with vehicle). The protein expression rate in individual treatments was
calculated as the ratio to beta-actin, and the rate in the control group was normalized to 1. (npo0.05 from nZ3).
Fig. 4. Cell growth response from combined treatment of 5-FU and DGLA's radical
derivatives. HCA-7 colony 29 cells were treated with 5-FU (0.25, 0.5 and 1.0 mM)
alone or 5-FU combined with DGLA's radical derivatives (1.0 μM) for 48 h. Cell
proliferation was assessed by the MTS assay. Cell viability was presented as the
percentage compared to control (treated with vehicle). Data represented three
separate experiments done in triplicate per condition.
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indicated that cellular D5D efﬁciently converted DGLA to AA during
our experiments. The conversion could restrict DGLA's anti-cancer
bioactivity [24] and also corresponded to formation of the highly
abundant hexanol radical (the common radical metabolite from
DGLA and AA peroxidation) and two low abundance DGLA-derived
radicals (the exclusive 8-HOA and HTA radicals). The observed
different amounts of free radicals from C-8 and C-15 oxygenation
in DGLA peroxidation may also be due to the different afﬁnities of
COX towards the two oxygenation mechanisms.
Depending on the product series, prostaglandins have been
reported to possess diverse activities, including pro- and anti-
cancer effects [5,11–12,15,17]. However, no effects of either PGE1
or 2 on cell proliferation were found under our experimental
conditions (Fig. 1), probably due to our low but more physiologi-
cally relevant concentrations compared to the other research
[15,17]. We believe that our concentrations were more appropri-
ately selected to test the cellular growth response. The formation
of free radicals during our experiments may be greatly under-
estimated by the cellular spin-trapping-based method. We are
currently working on a GC/MS-based analytical method to better
quantify DGLA's radical derivatives and assess their associated
activity. Considering all these factors, we propose that the exclu-
sive DGLA-derived radical metabolites from COX-catalyzed perox-
idation are likely to be at least partially responsible for DGLA's
anti-cancer bioactivity in physiological settings. We are also
conducting an experiment to quantify the non-free-radical meta-
bolites from COX-catalyzed DGLA peroxidation.
To investigate how DGLA's radical derivatives regulate colon
cancer cell growth, we examined the cell cycle distribution
and apoptosis. Our studies showed that the exclusive DGLA's
radical derivative (8-HOA) induces cell cycle arrest at the G1 phase
(Fig. 2), probably due to the induction of p27, a cyclin-dependent
kinase inhibitor. Another cell cycle inhibitor, p21, is also commonly
involved in cell cycle arrest at the G1/S phase and tightly controlled
by p53 [41,42]. We observed a signiﬁcantly up-regulated expres-
sion of p53 upon treatment with DGLA's radical derivatives (Fig. 3).
However, because the expression level of p21 in the experiments
was too low, we were unable to determine whether the p53-
dependent p21 pathway is also involved in arresting HCA-7 colony
29 cells in G1. We are now also conducting a mechanistic study on
the expression of these genes in order to understand the effect of
DGLA's radical derivative, and therefore DGLA peroxidation via
COX, on cell cycle progression.
Our apoptosis studies showed that the exclusive DGLA's radical
derivatives could induce cell apoptosis, most likely mediated by
the induction of p53, a cancer suppressor gene (Fig. 3). It has been
well documented that reactive lipid species from lipid peroxida-
tion can directly modify mitochondrial proteins and lead to
cytochrome c release [43,44]. Thus, we propose that the exclusive
DGLA's radical derivatives can interfere with mitochondrial pro-
teins and lead to cell apoptosis through mitochondrial pathways.
Pro-caspase 9, another mediator for cell apoptotic events, can be
cleaved into an active form via either p53-mediated or p53-
independent mechanisms, i.e., directly triggered by cytochrome c
release from mitochondria. However, no signiﬁcant changes were
observed in expression of pro-caspase 9 in cells from DGLA's
radical derivative treatments (Fig. 3).
5-FU is the most widely used chemo-drug for cancer therapy,
especially for colon cancer. However, the major limitation in
applying 5-FU in cancer therapy is its chemo-resistance. Evidence
shows that co-treatment with indomethacin and NS-398, both of
which are COX inhibitors, could signiﬁcantly sensitize colon cancer
cells to 5-FU, and that the regulation of COX-mediated PUFA
metabolism may be an effective strategy for overcoming 5-FU
chemo-resistance [31]. Here we have also tested the ability of
DGLA's radical derivatives to enhance 5-FU's cytotoxicity to HCA-7
colony 29 cells. A signiﬁcantly improved 5-FU IC50 was obtained
when the cells were treated with 5-FU combined with 8-HOA
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Fig. 5. Effect on cell apoptosis from combined treatment of 5-FU and DGLA's radical derivatives. A: Cell apoptosis analysis of HCA-7 colony 29 cells treated with 5-FU
(0.5 mM) alone or 5-FU combined with DGLA's radical derivatives (1.0 μM) for 48 h; B: p53 and pro-caspase 9 expression in Western blot upon different treatments for 48 h;
and C: Quantiﬁcation of p53 and pro-caspase 9 expression rate compared to control (treated with vehicle). The protein expression rate in individual treatments was
calculated as the ratio to beta-actin, and the rate in the control group was normalized to 1. (npo0.05 from nZ3).
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(Fig. 4). Our mechanism study has shown that the enhanced
cytotoxicity from the combination treatment may be due to the
enhanced induction of cell apoptosis triggered by an activation of
pro-caspase 9 (Fig. 5). Interestingly, 8-HOA alone did not inﬂuence
pro-caspase 9, while the combination of 8-HOA and 5-FU did
induce the activation of pro-caspase 9, probably independent of
p53 (Fig. 5).
COX is overexpressed in 480% of adenocarcinomas and has a
substantial association with cancer development [18–20]. COX
inhibition has become a conventional strategy for the treatment
of cancers, by virtue of its inhibition of the over-production of PGs-
2 (metabolites of COX/AA peroxidation). However, the results from
our series of work show that, under the catalysis of COX, DGLA can
produce beneﬁcial free radical metabolites associated with anti-
cancer activity. This new observation inspires us to take advantage
of the high COX expression in cancer cells to control cancer cell
growth by eliciting DGLA peroxidation to form exclusive DGLA's
radicals. In sum, the present study provides the ﬁrst evidence
demonstrating that the exclusive DGLA's free radical derivatives
could lead to cell growth inhibition, cell cycle arrest and apoptosis
in the HCA-7 colony 29 cell line from up-regulating the cancer
suppressor p53 and the cell cycle inhibitor p27. We also found that
the exclusive DGLA's free radical derivatives could signiﬁcantly
improve the cytotoxicity of 5-FU to cells insensitive to it. The
enhanced cytotoxicity observed from the combination treatment
may be due to enhanced induction of apoptosis triggered by
activation of pro-caspase 9. The outcome of this work may lead
us to the development of a novel drug combination strategy for
colon cancer therapy.
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